Identifying biomarkers for immune-related side effects in cancer patients receiving immunotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to identify predictive biomarkers for immune-related adverse events (irAEs) in patients undergoing treatment with immune checkpoint inhibitors (ICPI). By analyzing blood samples from cancer patients treated with ICPI, the research seeks to determine which individuals are at higher risk for developing severe immune toxicities. The findings could help tailor treatment plans and improve patient safety by identifying those who may need closer monitoring or alternative therapies. The study is conducted at the Amiens-Picardie University Hospital and Saint Quentin Hospital.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patient with cancer, whatever initial tumoral histology and disease stage under ICPI treatment (anti-PD1 and/or anti-CTLA-4)
* age \> 18
* followed in oncology, pneumology, dermatology, gastroenterology departments of Amiens-Picardie University Hospital or Saint Quentin hospital
* who received verbal and written information, and signed the consent form for the study

Exclusion Criteria:

* non ICPI treated patients
* patient who received a first line of ICPI treatment
* patient who received or is receiving MEK inhibitors as a treatment (because of possible lower response to ICPI treatment when associated)

Where it's running

• CHU Amiens Picardie
  Amiens, Picardie, France Recruiting

Study contacts

• Study coordinator: Gwladys BOURDENET, DR
• Email: bourdenet.gwladys@chu-amiens.fr
• Phone: 03.22.08.70.72

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC

  This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07894458

• PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer

  This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT07884877

• FAPI-guided radiotherapy with cadonilimab plus chemo for colorectal cancer limited to the peritoneum

  Aims to see if adding targeted radiotherapy and cadonilimab immunotherapy to standard second-line chemotherapy helps adults with colorectal cancer that’s spread only to the peritoneum.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07815834

• Adjuvant sintilimab after neoadjuvant therapy and surgery for high-risk NSCLC

  This trial tests whether giving sintilimab after surgery helps prevent cancer from returning in people with high-risk non-small cell lung cancer who already had neoadjuvant immunochemotherapy and surgery.

  Recruiting at 2 sites Phase 2 Sichuan University · Chengdu, Sichuan and 1 other locations · NCT07748325

• Predictive biomarkers for immunotherapy in endometrial cancer

  This study tests molecular and epigenetic features to see if they can predict which endometrial cancer patients will respond to immune checkpoint inhibitors.

  Recruiting European Institute of Oncology · Milan, Italy · NCT07690540

• Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in Localized Rectal Cancer

  In people with locally advanced, treatment-naive rectal cancer, this study tests whether adding two immunotherapy drugs to a standard chemotherapy after short-course radiotherapy can improve tumor response.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07686640

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.